Terumo BCT and Marker Therapeutics Receive the US FDA’s Emergency Use Authorization for their Purification Device to Treat COVID-19

Terumo BCT and Marker Therapeutics Receive the US FDA’s Emergency Use Authorization for their Purification Device to Treat COVID-19

Shots:

  • The US FDA has granted EUA to Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged ≥18yrs. with confirmed COVID-19 and are admitted to the ICU with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels
  • The device works by reducing the number of cytokines and other inflammatory mediators in the blood, filter it and return the filtered blood to the patient
  • The two companies collaborate to combine their existing technologies for providing a unique solution for the treatment of acute respiratory failure in COVID-19

Click here to­ read full press release/ article | Ref: Terumo BCT | Image: Terumo BCT